Raw Mavacamten Powder

Introduction to the Product

Mavacamten is a medication used in the treatment of hypertrophic cardiomyopathy (HCM), a genetic heart condition characterized by abnormal thickening of the heart muscle.

Here are key points about mavacamten:

1. Mechanism of Action:

Mavacamten works by inhibiting the enzyme myosin ATPase, which is involved in the contraction of heart muscle cells. By inhibiting this enzyme, mavacamten reduces the excessive contractility (hypercontractility) of the heart muscle seen in HCM. This helps to improve the heart's ability to pump blood effectively and reduces symptoms associated with HCM, such as shortness of breath and chest pain.

2. Clinical Use:

Mavacamten is primarily indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM), where the thickening of the heart muscle obstructs the flow of blood from the left ventricle to the aorta during systole (when the heart contracts). It is also being studied for its potential benefits in non-obstructive HCM (nHCM).

3. Approval:

In January 2022, mavacamten (brand name MyoKardia) received approval from the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic oHCM in adults.

4. Clinical Trials:

The approval of mavacamten was based on clinical trials demonstrating its efficacy in improving symptoms and exercise capacity in patients with oHCM. Ongoing research continues to explore its long-term effects and benefits in different patient populations.

5. Side Effects:

Common side effects of mavacamten may include headache, dizziness, nausea, diarrhea, and abnormal liver function tests. Serious side effects, though rare, can include low blood pressure and abnormal heart rhythms.

6. Monitoring:

Patients taking mavacamten may require regular monitoring, including cardiac assessments and blood tests, to evaluate treatment response and detect any potential adverse effects.

In summary, mavacamten is a novel medication approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Its mechanism of action targets the underlying hypercontractility of the heart muscle, providing a new therapeutic option for patients with this genetic heart condition.

Jinan Jianfeng Chemical Co.,Ltd. is a leading researeh-driven family-managed pharmaceutical company, In the principle of "Quality Oriented" , Jianfeng passed the certification of ISO9001:2008 Quality Management System. The products meet USP, EP, JP and CP standards and are available not only in China but also in the US, Germany, Canada Japan, etc. To meet market demands, Jianfeng set up one R&D center, two GMP workshops and three pharmaceutical & chemical factories.

"Honesty, practicality, innovation, development" are our values, Jianfeng would like to cooperate with you with high quality produets and competitive price.

Mr. Lee​

​-Sales manager

Tel, Whatsapp, Wechat:​​​ +8613153002107

Mail: sales09@pharmachemm.com

​Web:​​www.jianfengchemical.com

Addr: ​311-2, R&D Building 1, No. 554 Zhengfeng road, High-

Tech zone,Jinan City, Shandong, China.

Hot Tags: raw mavacamten powder, China, suppliers, manufacturers, factory, wholesale, buy, bulk, price, for sale, in stock, Lidocaine Hcl Powder, Hydralazine Hcl Powder, Loteprednol Powder, Lapatinib Ditosylate Powder, 99 9 Pure Tetracaine Powder, Antifungal Nifuratel Powder